69188
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 7
- e1_e2
- E2
- umap1_2d
- -5.303420929
- umap2_2d
- 1.126802932
- umap1_3d
- -0.348490347
- umap2_3d
- 3.190808406
- umap3_3d
- -0.314729036
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.380
- INTERFERON_GAMMA_RESPONSE+0.370
- UV_RESPONSE_DN+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- COMPLEMENT+0.320
- APOPTOSIS+0.300
- TGF_BETA_SIGNALING+0.300
- ALLOGRAFT_REJECTION+0.290
- CHOLESTEROL_HOMEOSTASIS+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.390
- OXIDATIVE_PHOSPHORYLATION-0.220
- PANCREAS_BETA_CELLS-0.210
- SPERMATOGENESIS-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.160
- HYPOXIA-0.130
- APICAL_SURFACE-0.110
- MYC_TARGETS_V1-0.110
- ADIPOGENESIS-0.100
- E2F_TARGETS-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3280 | Med | Medulloblastoma | 0.855 |
| 2 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.845 |
| 3 | BS_9HA238XS | Neurofibroma | — | 0.843 |
| 4 | MDT-AP-0390 | Med | Medulloblastoma | 0.839 |
| 5 | BS_49VCQD19 | Neurofibroma | — | 0.834 |
| 6 | TCGA-86-8074-01A-11R-2241-07 | — | cohortA1 | 0.832 |
| 7 | R223 | — | — | 0.829 |
| 8 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.828 |
| 9 | MNG664 | — | — | 0.826 |
| 10 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |